Trulieve Cannabis Corp. (TSE:TRU – Free Report) – Equities researchers at Seaport Res Ptn issued their Q1 2025 EPS estimates for shares of Trulieve Cannabis in a research note issued to investors on Wednesday, March 5th. Seaport Res Ptn analyst S. Randhawa forecasts that the company will earn ($0.07) per share for the quarter. Seaport Res Ptn also issued estimates for Trulieve Cannabis’ Q2 2025 earnings at ($0.04) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at $0.03 EPS, FY2025 earnings at ($0.13) EPS, Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at ($0.01) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.01 EPS and FY2026 earnings at ($0.04) EPS.
Several other analysts also recently issued reports on TRU. Atb Cap Markets raised Trulieve Cannabis from a “hold” rating to a “strong-buy” rating in a report on Monday, December 9th. Cormark upgraded Trulieve Cannabis from a “hold” rating to a “moderate buy” rating in a research note on Monday, March 3rd. Craig Hallum upgraded shares of Trulieve Cannabis to a “strong-buy” rating in a research report on Wednesday, February 26th. Finally, Roth Capital raised shares of Trulieve Cannabis to a “strong-buy” rating in a report on Monday, March 3rd.
Trulieve Cannabis Stock Performance
Insider Buying and Selling
In other news, Senior Officer Wes Getman bought 9,500 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The shares were purchased at an average price of C$7.02 per share, with a total value of C$66,702.35.
About Trulieve Cannabis
TransUnion provides risk and information solutions. The company operates in three segments: U.S. Markets, International, and Consumer Interactive. The U.S. Markets segment provides consumer reports, actionable insights, and analytics to businesses. These businesses use its services to acquire new customers; assess consumer ability to pay for services; identify cross-selling opportunities; measure and manage debt portfolio risk; collect debt; verify consumer identities; and mitigate fraud risk.
Featured Stories
- Five stocks we like better than Trulieve Cannabis
- What is a buyback in stocks? A comprehensive guide for investors
- Institutional Investors Bet $1B on These 4 Stocks—Should You?
- How to Most Effectively Use the MarketBeat Earnings Screener
- One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
Receive News & Ratings for Trulieve Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trulieve Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.
